Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | GNAS complex locus | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Schistosoma mansoni | GTP-binding protein alpha subunit gna | GNAS complex locus | 394 aa | 450 aa | 28.7 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus multilocularis | ubiquinone biosynthesis monooxygenase COQ6 | 0.0095 | 0.5 | 0.5 |
Mycobacterium ulcerans | membrane-associated oxidoreductase | 0.0095 | 0.5 | 0.5 |
Mycobacterium tuberculosis | Possible oxidoreductase | 0.0095 | 0.5 | 0.5 |
Toxoplasma gondii | FAD binding domain-containing protein | 0.0095 | 0.5 | 0.5 |
Mycobacterium tuberculosis | Probable oxidoreductase | 0.0095 | 0.5 | 0.5 |
Mycobacterium ulcerans | hypothetical protein | 0.0095 | 0.5 | 0.5 |
Mycobacterium ulcerans | hypothetical protein | 0.0095 | 0.5 | 0.5 |
Mycobacterium ulcerans | oxidoreductase | 0.0095 | 0.5 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0095 | 0.5 | 0.5 |
Plasmodium vivax | FAD-dependent monooxygenase, putative | 0.0095 | 0.5 | 0.5 |
Plasmodium falciparum | FAD-dependent monooxygenase, putative | 0.0095 | 0.5 | 0.5 |
Leishmania major | hypothetical protein, conserved | 0.0095 | 0.5 | 0.5 |
Mycobacterium leprae | possibleputative FAD-linked oxidoreductase | 0.0095 | 0.5 | 0.5 |
Trypanosoma brucei | kynurenine 3-monooxygenase, putative | 0.0095 | 0.5 | 0.5 |
Mycobacterium ulcerans | oxidoreductase GMC-type | 0.0095 | 0.5 | 0.5 |
Trypanosoma cruzi | Monooxygenase, putative | 0.0095 | 0.5 | 0.5 |
Mycobacterium ulcerans | FAD-linked oxidoreductase | 0.0095 | 0.5 | 0.5 |
Mycobacterium tuberculosis | Possible oxidoreductase | 0.0095 | 0.5 | 0.5 |
Leishmania major | hypothetical protein, conserved | 0.0095 | 0.5 | 0.5 |
Mycobacterium ulcerans | hypothetical protein | 0.0095 | 0.5 | 0.5 |
Mycobacterium ulcerans | oxidoreductase | 0.0095 | 0.5 | 0.5 |
Toxoplasma gondii | FAD binding domain-containing protein | 0.0095 | 0.5 | 0.5 |
Echinococcus granulosus | protein MICAL 3 | 0.0095 | 0.5 | 0.5 |
Trypanosoma brucei | Monooxygenase, putative | 0.0095 | 0.5 | 0.5 |
Plasmodium vivax | hypothetical protein, conserved | 0.0095 | 0.5 | 0.5 |
Echinococcus multilocularis | protein MICAL 3 | 0.0095 | 0.5 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0095 | 0.5 | 0.5 |
Mycobacterium tuberculosis | Probable oxidoreductase | 0.0095 | 0.5 | 0.5 |
Trypanosoma cruzi | hypothetical protein, conserved | 0.0095 | 0.5 | 0.5 |
Mycobacterium ulcerans | FAD-dependent oxidoreductase | 0.0095 | 0.5 | 0.5 |
Echinococcus granulosus | ubiquinone biosynthesis monooxygenase COQ6 | 0.0095 | 0.5 | 0.5 |
Schistosoma mansoni | monoxygenase | 0.0095 | 0.5 | 0.5 |
Mycobacterium tuberculosis | Possible oxidoreductase | 0.0095 | 0.5 | 0.5 |
Wolbachia endosymbiont of Brugia malayi | 2-polyprenyl-6-methoxyphenol 4-hydroxylase | 0.0095 | 0.5 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 1.2589 uM | PubChem BioAssay. qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS. (Class of assay: confirmatory) | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.